Scientists have long wondered why almost all animals sleep, despite the disadvantages to survival of being unconscious. Now, researchers led by a team from the University of Tsukuba… read more.
Anxiety, addiction, and other psychiatric disorders are often characterized by intense states of what scientists call arousal: The heart races, blood pressure readings rise, breaths shorten, and “bad”… read more.
Impel NeuroPharma, Inc. announced that the FDA approved Trudhesa (dihydroergotamine mesylate) nasal spray (0.725 mg per spray) for the acute treatment of migraine with or without aura in… read more.
For millions of people with epilepsy and movement disorders such as Parkinson’s disease, electrical stimulation of the brain already is widening treatment possibilities. In the future, electrical stimulation… read more.
University of California San Francisco Technology could lead to more natural communication for people who have suffered speech loss Researchers at UC San Francisco have successfully developed a… read more.
Researchers report in a newly published study of vasovagal syncope in younger, otherwise healthy patients, that treatment with oral midodrine significantly decreases fainting spells. Vasovagal syncope is the… read more.
Jazz Pharmaceuticals plc announced that the FDA approved Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution for the treatment of idiopathic hypersomnia in adults. The company plans… read more.
The FDA has approved fexinidazole as the first all-oral treatment for both stages of the Trypanosoma brucei gambiense form of sleeping sickness (Human African trypanosomiasis) in patients 6… read more.
Kyowa Kirin Co., Ltd. has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion for istradefylline as an… read more.
It’s so commonplace we barely give it a second thought, but human brains seem hardwired to see human faces where there are none — in objects as varied… read more.
Université de Genève One person in 2000 suffers from a microdeletion of chromosome 22 that can lead to the development of psychotic disorders, such as schizophrenia, in adolescence…. read more.